Efficacy of Lanreotide Depot/Autogel for Symptomatic Control of Carcinoid Syndrome (CS) in Neuroendocrine Tumor Patients: Follow-up Analysis of the ELECT Prospective, Randomized, Double-blind and Open-label Phases Fisher, G. A., Wolin, E. M., Kunz, P. L., Liyanage, N., Mirakhur, B., Lowenthal, S., Pommier, R. F., Shaheen, M., Vinik, A. LIPPINCOTT WILLIAMS & WILKINS. 2017: 433–34

View details for Web of Science ID 000394448600052